IRIS

1.5 Abstract in Rivista: [1819] Home page tipologia

Sfoglia
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 461 a 480 di 1.819
Titolo Data di pubblicazione Autore(i) File
Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP) 1-gen-2017 De Giorgi, U; Scagliarini, S; Basso, U; Galli, L; Mosillo, C; Caserta, C; Rossetti, S; Guida, A; Bearz, A; Buti, S; Lo Re, G; Valcamonico, F; Hamzaj, A; Cognetti, F; Rastelli, F; Fornarini, G; Porta, C; Del Bene, G; Turci, D; Procopio, G
Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC) 1-gen-2007 Longarini, R; Buti, S; Bosio, G; Brighenti, M; Porzio, R; Negri, F; Passalacqua, R
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors 1-gen-2017 Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials 1-gen-2011 Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crinò, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, E on bealf of GOIRC and NVALT groups
Renal metastases to pancreas: do not operate all and always? 1-gen-2014 Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S
The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study 1-gen-2017 Vitale, Mg; Masini, C; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report 1-gen-2014 Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study 1-gen-2007 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) 1-gen-2015 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Maintenance biotherapy for metastatic renal cancer with IL-2 and IFN-alpha: A Phase III, randomized, multicentre trial 1-gen-2004 Passalacqua, R; Buzio, C; Labianca, R; Porta, C; Dalla Chiesa, M; Buti, S; Tomasello, G; Camisa, R; Frassoldati, A; Caminiti, C
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab 1-gen-2017 Tiseo, M; Veneziani, M; Gelsomino, F; Facchinetti, F; Bordi, P; Rapacchi, E; Squadrilli, A; Buti, S; Missale, G; Ardizzoni, A
Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients 1-gen-2012 Bordi, P; Buti, S; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, S; Pilotto, S; Camisa, R; Ardizzoni, A
Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial 1-gen-2007 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R
Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD) 1-gen-2013 Masini, C; Porta, C; Milella, M; Procopio, G; Di, Lorenzo G; Santoni, M; Buti, S; Iacovelli, R; Invernizzi, R; Moscetti, L; Aste, Mg; Pagano, M; Grosso, F; Manenti, Al; Ortega, C; Cosmai, L; Nicodemo, M; Donati, D; Del Giovane, C; Sabbatini, R
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents 1-gen-2017 Grassi, P; Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Ratta, R; Procopio, G
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers 1-gen-2009 Brighenti, M; Passalacqua, R; Naldi, N; Buti, S; Lazzarelli, S; Potenzoni, D; Potenzoni, M; Benecchi, L; Fumagalli, M; Losardo, ; Monica, B; Caminiti, C
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial 1-gen-2012 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib) 1-gen-2008 Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report 1-gen-2014 Bracarda, S; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Harnzaj, A; Altavilla, A; De Angelis, V
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial 1-gen-2007 Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R
Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 461 a 480 di 1.819
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile

Scopri
Tipologia
  • 1 Articolo su rivista1819
Autore
  • DI MARIO, Francesco242
  • BUTI, Sebastiano150
  • GIULIANI, Nicola130
  • ALBERTINI, Roberto87
  • SEBASTIANI, MARCO85
  • SCARPIGNATO, Carmelo75
  • AGNETTI, Aldo66
  • PARRINO, Liborio66
  • MUSOLINO, Antonino61
  • CARANO, Nicola60
Data di pubblicazione
  • 2020 - 2026208
  • 2010 - 2019847
  • 2000 - 2009537
  • 1990 - 1999175
  • 1980 - 198951
  • 1979 - 19791
Editore
  • ELSEVIER25
  • Elsevier17
  • SAGE PUBLICATIONS LTD17
  • DIKE GIURIDICA15
  • ASCO pubs11
  • ELSEVIER IRELAND LTD7
  • ASCO6
  • ELSEVIER SCIENCE INC5
  • SAGE5
  • SPRINGERNATURE4
Rivista
  • DIGESTIVE AND LIVER DISEASE101
  • GASTROENTEROLOGY100
  • ANNALS OF ONCOLOGY94
  • BLOOD91
  • HAEMATOLOGICA59
  • JOURNAL OF CLINICAL ONCOLOGY58
  • NEUROLOGICAL SCIENCES47
  • UNITED EUROPEAN GASTROENTEROLOGY ...46
  • ANNALS OF THE RHEUMATIC DISEASES36
  • EPILEPSIA26
Keyword
  • Helicobacter pylori10
  • epilepsy9
  • sclerosi sistemica6
  • Bioengineering5
  • Gastroenterology5
  • HCV5
  • temporal lobe epilepsy5
  • UV5
  • GERD4
  • Lungs4
Lingua
  • eng969
  • ita176
  • fre1
Accesso al fulltext
  • no fulltext1787
  • reserved26
  • open6